Liu Tianzhu, Chen Li, Deng Shiyu, He Jie, Li Dekang, Chen Yunbo
Neurological Disease Center, Zigong Fourth People's Hospital, Zigong, 643000, Sichuan, China.
Department of neurology, Traditional Chinese Medicine Hospital of Gaoxian, Yibin, 645154, Sichuan, China.
Thromb J. 2024 Oct 3;22(1):86. doi: 10.1186/s12959-024-00660-1.
Carotid artery stenting (CAS) is a key treatment option for moderate to severe carotid artery stenosis. Carotid stent thrombosis (CST), a rare complication of CAS, has gained significant attention because of its catastrophic nature. More evidences are needed to guide the diagnosis and treatment of CST.
This study reports a rare case of sub-acute CST following CAS in a 50-year-old male patient who had experienced repeated cerebrovascular events on the premise of taking antiplatelet drugs. He also suffered an occlusion of the left middle cerebral artery (MCA) in the M2 segment, likely caused by an embolus detached from the stent thrombus. The cause of CST in this patient was presumed to be dual antiplatelet resistance (AR), as indicated by genetic testing. After treated with guide catheter-directed thrombolysis, thrombus aspiration, and a second round of thrombolysis, his in-stent thrombus was basically cleared. His M2 occlusion was resolved by mechanical thrombectomy using the Solitaire FR/Stent with Intermediate Catheter Assisting technique. The patient recovered well after replacement of antiplatelet drugs, and no new thromboembolic event occurred during the 13-month follow-up period.
The occurrence rate of AR-related CST may be underestimated as the cause of majority CST cases remains unclear. Implementation of genetic test for aspirin and clopidogrel resistance may be helpful to find the possible cause of CST and to avoid future repeated cerebrovascular events by replacement of antiplatelet drugs.
颈动脉支架置入术(CAS)是治疗中重度颈动脉狭窄的关键选择。颈动脉支架血栓形成(CST)是CAS的一种罕见并发症,因其灾难性后果而备受关注。需要更多证据来指导CST的诊断和治疗。
本研究报告了一例50岁男性患者在CAS术后发生亚急性CST的罕见病例,该患者在服用抗血小板药物的前提下仍反复发生脑血管事件。他还出现了左侧大脑中动脉(MCA)M2段闭塞,可能是由支架血栓脱落的栓子所致。基因检测表明,该患者CST的原因推测为双重抗血小板抵抗(AR)。经引导导管直接溶栓、血栓抽吸和第二轮溶栓治疗后,其支架内血栓基本清除。采用Solitaire FR/支架联合中间导管辅助技术进行机械取栓,解决了他的M2段闭塞问题。更换抗血小板药物后患者恢复良好,在13个月的随访期内未发生新的血栓栓塞事件。
由于大多数CST病例的病因尚不清楚,AR相关CST的发生率可能被低估。开展阿司匹林和氯吡格雷抵抗的基因检测可能有助于找出CST的可能病因,并通过更换抗血小板药物避免未来反复发生脑血管事件。